Preclinical studies, specifically in pituitary and pancreatic adenocarcinoma cells, have demonstrated synergistic effects through dual inhibition of the PI3K/AKT/mTOR pathway. This evidence concerns the gene AKT1 and pancreatic adenocarcinoma.